why choose us

First received: July 08, 2024

Clinical Trial: A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Overweight and Obesity

Study Type: INTERVENTIONAL


Official Title: A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered

Brief Summary: Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1.On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide).Participants will remain at the clinical research unit for the duration of the treatment period.The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a GLP-1 agonist, in…

Read more